Welcome to our dedicated page for Curative Biotechnology news (Ticker: CUBT), a resource for investors and traders seeking the latest updates and insights on Curative Biotechnology stock.
Curative Biotechnology, Inc. (OTC: CUBT) is a development-stage biomedical company focused on novel therapies for rare diseases, with programs in degenerative eye disease, infectious disease, and neuro-oncology. The CUBT news feed on this page aggregates company-issued updates and other coverage so readers can follow how its pipeline and strategy evolve over time.
Recent news has highlighted Curative Biotech’s emphasis on its degenerative eye disease platform, built on a worldwide exclusive license from the National Eye Institute (NEI) at the NIH. Articles cover progress with its metformin-based ophthalmic reformulation for intermediate and late-stage Age-Related Macular Degeneration (AMD), including completion of IND-enabling toxicology work, a planned first-in-human trial under a CRADA with the NEI, and the filing of a PCT patent application for an ophthalmic formulation capable of delivering metformin to the choroid, RPE, and retina.
News items also describe corporate and strategic developments, such as the establishment of Curative Biotech Japan K.K. to support licensing and asset acquisitions in Japan, the engagement of Golden Eagle Capital Advisors, Inc. as exclusive agent and strategic advisor, and updates on capital structure, including withdrawal of a planned S-1 offering and revisions to a proposed reverse stock split. Governance-focused releases detail the nomination or appointment of independent directors with ophthalmology and biotechnology experience and the creation of a Clinical Development Committee of the Board.
Investors and observers can use this page to review Curative Biotech’s announcements on clinical planning, licensing strategy, veterinary ophthalmology initiatives in canine retinal diseases, and capital markets intentions, all in one place. Bookmark this feed to quickly reference historical and ongoing CUBT news as the company advances its development-stage programs.
Curative Biotechnology (CUBT) announced Dr. Catherine Sohn's appointment as a Special Advisor to its Board of Directors on October 12, 2021. Dr. Sohn, with over 30 years of biopharmaceutical experience, will oversee the company's infectious disease and macular degeneration programs. Paul Michaels, Chairman, emphasized her strategic background in vaccine development, particularly for the next-generation COVID-19 vaccine targeting kidney failure patients. This appointment aims to accelerate Curative's novel treatments for rare diseases and conditions, including a promising rabies therapeutic.
Curative Biotechnology (CUBT) has expanded its licensing agreement with Mid-Atlantic BioTherapeutics to include the development of a next-generation COVID-19 vaccine targeting kidney failure patients. This initiative addresses the need for tailored vaccines for immunocompromised individuals, who often have poor responses to existing vaccines. Curative Biotech also holds worldwide rights to develop IMT504 for treating symptomatic rabies, with orphan drug designation received in the US. The company aims to enhance its clinical development team in upcoming announcements.
Curative Biotechnology (CUBT) has entered into a licensing agreement with Mid-Atlantic BioTherapeutics (MABT) to develop a next-generation COVID-19 vaccine specifically targeting kidney failure patients, who are particularly vulnerable to severe COVID-19. This new vaccine will utilize IMT504 as an adjuvant in its formulation. The partnership expands Curative Biotech's portfolio, which already includes treatments for rabies and degenerative eye diseases. The press release highlights the urgent need for tailored vaccines for immunocompromised populations, with implications for both public health and potential market opportunities.
Curative Biotechnology, Inc. (OTC: CUBT) has appointed Dr. Nicholas Boulis, MD/PhD, to its Scientific and Clinical Advisory Board, enhancing its clinical program for a CD56 monoclonal antibody drug conjugate aiming to treat glioblastoma. Dr. Boulis, affiliated with Emory University and renowned for his expertise in neural gene therapy, is expected to work alongside Dr. Dimiter Dimitrov, the lead inventor, to advance the glioblastoma program. The company focuses on innovative treatments for rare diseases, aiming for accelerated development paths.
Curative Biotechnology (OTC: CUBT) announced that Marc Drimer, CPA, has joined its Board of Directors as an independent director and Chairman of the Audit Committee. With over 35 years of experience in corporate governance and finance, Drimer has had significant roles in international firms. His expertise includes financial operations and managing public offerings. Chairman Paul M. Michaels noted that Drimer's addition marks a vital milestone for the company as it seeks to explore capital market opportunities and advance its therapeutic pipeline aimed at rare diseases.
Curative Biotechnology (CUBT) released its Q1 quarterly report for the period ending March 31, 2021. Key highlights include a significant increase in cash reserves from $160,607 to $564,546 and a reduction in debt from $528,893 to $75,373. The company successfully converted Series A and B Preferred shares to Common, strengthening its equity structure. The management team has expanded, adding seasoned professionals to direct its therapeutic development efforts, particularly in rare diseases including rabies and glioblastoma. Curative Biotech is set to file an IND with the FDA for a new retinal degeneration treatment by year-end.
Curative Biotechnology (OTC: CUBT) announced a trading symbol change from CTYX to CUBT and a corporate name change to better reflect its mission in rare disease therapeutics. Chairman Paul Michaels emphasized the transformation in mission and leadership with the addition of renowned scientists Dr. Kapil Bharti and Dr. Dimiter Dimitrov to the Scientific and Clinical Advisory Board. Bharti is noted for developing treatments for eye diseases, while Dimitrov focuses on antibody therapeutics. Curative plans to file an IND for a metformin reformulation to treat wet AMD.
Curative Biotechnology, Inc. (OTC: CUBT) announced a trading symbol change from CTYX to CUBT as part of its rebranding efforts. This name change reflects the company's mission to develop novel therapies for rare diseases. The company also appointed two experts to its Scientific and Clinical Advisory Board: Dr. Kapil Bharti and Dr. Dimiter Dimitrov, who will guide pre-clinical and clinical trials. Additionally, Curative plans to file an Investigational New Drug Application for a reformulated metformin treatment for wet Age-related Macular Degeneration by year-end.